Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

A legfontosabb adatok

Ki végzi
Sanofi
Hol
Belgium, Franciaország, Lengyelország, Németország, Portugália és Spanyolország61 helyszín, 6 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
6000 fő, tervezett
Kezdés
2026. okt. 28.
Várható befejezés
2027. dec. 28.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • IIV-HD (standalone)
  • NVXC19 (EU licensed, standalone)
  • IIV-HD + NVXC19 combination
  • Placebo, normal saline
A regiszteradat frissítve
2026. november 13.

Ki vehet részt

Életkor
60 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Aged 60 years or older on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
  • Aged 60 years or older on the day of inclusion
  • Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
  • Non-childbearing potential (i.e., post-menopausal for at least 1 year or surgically sterile)
  • lnformed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine

Ki nem vehet részt

  • Known/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
  • Any vaccine given within 4 weeks before or within 4 weeks after study intervention
  • Previous vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
  • Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
  • Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
  • Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved
  • History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
  • Personal or family history of Guillain-Barré syndrome
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
  • Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
  • Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.

A teljes eredeti leírásKevesebb

Study details include:

* The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01

A vizsgálat 2 csoportja

  • Group 1, IIV-HD and EU-licensed NVXC19Már használt kezelés, összehasonlításként

    IIV-HD and NVXC19 co-administered in opposite deltoid muscles

    Kezelés: IIV-HD (standalone) és NVXC19 (EU licensed, standalone)

  • Group 2, IIV-HD + NVXC19 combination and placeboA vizsgált kezelés

    IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles

    Kezelés: IIV-HD + NVXC19 combination és Placebo, normal saline

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
A regiszteradat frissítve
2026. november 13.